Autologous Cell Therapy Market (By Source: Epidermis, Bone Marrow, Mesenchymal Stem Cells, Haematopoietic Stem Cells, Chondrocytes, Others; By Application: Cancer, Cardiovascular Disorders, Neurodegenerative Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Others; By End-Use: Hospitals & Clinics, Ambulatory Centers, Academics & Research, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Autologous Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Autologous Cell Therapy Market Revenue and Volume, by Source, 2024-2033
8.1.1 Epidermis
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Bone Marrow
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Mesenchymal Stem Cells
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Haematopoietic Stem Cells
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
8.1.5. Chondrocytes
8.1.5.1. Market Revenue and Volume Forecast (2021-2033)
8.1.6. Others
8.1.6.1. Market Revenue and Volume Forecast (2021-2033)
9.1. Autologous Cell Therapy Market Revenue and Volume, by Application, 2024-2033
9.1.1. Cancer
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Cardiovascular Disorders
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Neurodegenerative Disorders
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. Autoimmune Disorders
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. Orthopedics
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
9.1.6. Wound Healing
9.1.6.1. Market Revenue and Volume Forecast (2021-2033)
9.1.7. Others
9.1.7.1. Market Revenue and Volume Forecast (2021-2033)
10.1. Autologous Cell Therapy Market Revenue and Volume, by End-Use, 2024-2033
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Ambulatory Centers
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Academics & Research
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Source (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)
12.1. Autolus Therapeutics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Lineage Cell Therapeutics, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sangamo Therapeutics
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Holostem Terapie Avanzate S.r.l.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Vericel Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Opexa Therapeutics
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. BrainStorm Cell Therapeutics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pharmicell Co., Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Bayer AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Daiichi Sankyo Co., Ltd
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample